Nuclear (Scintigraphic) Methods and fdg-pet in Rheumatoid Arthritis And Osteoarthritis

Arthritis in Color

Volumn , Issue , 2009, Pages 138-149

  Ribbens, Clio ^a   Hustinx, Roland ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955014100     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4722-3.00007-0     Document Type: Chapter

References (45)

1. O'Connor MK, Brown ML, Hung JC, Hayostek RJ The art of bone scintigraphy: technical aspects. J Nucl Med 1991, 32:2332-2341.
2. Rosenthall L Nuclear medicine techniques in arthritis. Rheum Dis Clin North Am 1991, 17:585-597.
3. Desaulniers M, Fuks A, Hawkins D, et al. Radiotechnetium polyphosphate joint imaging. J Nucl Med 1974, 15:417-423.
4. 99mtechnetium methylene diphosphonate in rheumatoid arthritis. J Rheumatol 1982, 9:939-941.
5. Sewell KL, Ruthazer R, Parker JA The correlation of indium-111 joint scans with clinical synovitis in rheumatoid arthritis. J Rheumatol 1993, 20:2015-2019.
6. Jamar F, Houssiau FA, Devogelaer JP, et al. Scintigraphy using a technetium 99m-labelled anti-E-selectin Fab fragment in rheumatoid arthritis. Rheumatology 2002, 41:53-61.
7. 99mTc-labeled interleukin-8 for the scintigraphic detection of infection and inflammation: first clinical evaluation. J Nucl Med 2007, 48:337-343.
8. Firestein GS, Yeo M, Zvaifler NJ Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995, 96:1631-1638.
9. Post AM, Katsikis PD, Tait JF, et al. Imaging cell death with radiolabeled Annexin V in an experimental model of rheumatoid arthritis. J Nucl Med 2002, 43:1359-1365.
10. Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002, 8:2766-2774.
11. Duer A, Østergaard M, Vallo J, Horslev-Petersen K Magnetic resonance imaging and bone scintigraphy in the differential diagnosis of unclassified arthritis. Ann Rheum Dis 2008, 67:48-51.
12. Hustinx R, Malaise MG PET imaging of arthritis. PET Clin North Am 2006, 1:131-139.
13. 18F-FDG PET/CT examinations. J Nucl Med 2005, 46:608-613.
14. Zhao S, Kuge Y, Tsukamoto E, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med 2001, 28:730-735.
15. Zhao S, Kuge Y, Tsukamoto E, et al. Fluorodeoxyglucose uptake and glucose transporter expression in experimental inflammatory lesions and malignant tumours: effects of insulin and glucose loading. Nucl Med Commun 2002, 23:545-550.
16. 18F-FDG PET. J Nucl Med 2004, 45:956-964.
17. Palmer WE, Rosenthal DI, Schoenberg OI, et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy -d-glucose. Radiology 1995, 196:647-655.
18. Zhuang H, Alavi A 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002, 32:47-59.
19. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by autoradiography. J Nucl Med 1992, 33:1972-1980.
20. Kubota R, Kubota K, Yamada S, et al. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 1994, 35:104-112.
21. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995, 36:1301-1306.
22. Gamelli RL, Liu H, He LK, Hofmann CA Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 1996, 59:639-647.
23. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001, 42:1551-1555.
24. Wipke BT, Wang Z, Kim J, et al. Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nature Immunol 2002, 3:366-372.
25. Yasuda S, Shohtsu A, Ide M, et al. F-18 FDG accumulation in inflamed joints. Clin Nucl Med 1996, 21:740.
26. Bakheet SMB, Powe J Fluorine-18-fluorodeoxyglucose uptake in rheumatoid-arthritis-associated lung disease in a patient with thyroid cancer. J Nucl Med 1998, 39:234-236.
27. 18F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging 2006, 33:275-280.
28. Ribbens C, Andre B, Marcelis S, et al. Rheumatoid hand joint synovitis, gray-scale and power Doppler US quantifications following anti-tumor necrosis factor-alpha treatment: pilot study. Radiology 2003, 229:562-569.
29. Cimmino MA, Innocenti S, Livrone F, et al. Dynamic gadolinium-enhanced magnetic resonance imaging of the wrists in patients with rheumatoid arthritis can discriminate active from inactive disease. Arthritis Rheum 2003, 48:1207-1213.
30. Ribbens C, Martin y Porras M, Franchimont N, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002, 61:161-166.
31. Østergaard M, Stoltenberg M, Lovgreen-Nielsen P, et al. Quantification of synovitis by MRI: correlation between dynamic and static gadolinium-enhanced magnetic resonance imaging and microscopic and macroscopic signs of synovial inflammation. Magn Reson Imaging 1998, 16:753-758.
32. Gaffney K, Cookson J, Blades S, et al. Quantitative assessment of the rheumatoid synovial microvascular bed by gadolinium-DTPA enhanced magnetic resonance imaging. Ann Rheum Dis 1998, 57:152-157.
33. 18F-fluoro-2-deoxy -d-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum 2003, 48:3077-3084.
34. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
35. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003, 42:244-257.
36. Yun M, Kim W, Adam L, et al. F-18 FDG uptake in a patient with psoriatic arthritis: imaging correlation with patient symptoms. Clin Nucl Med 2001, 26:692-693.
37. Beckers C, Bernard C, Kaiser MJ, et al. Time-course study of [F-18]-FDG uptake in psoriatic synovitis. J Nucl Med 2005, 46(Suppl 2):183P.
38. Wandler E, Kramer EL, Sherman O, et al. Diffuse FDG shoulder uptake on PET is associated with clinical findings of osteoarthritis. AJR Am J Roentgenol 2005, 185:797-803.
39. Nakamura H, Masuko K, Yudoh K, et al. Positron emission tomography with 18F-FDG in osteoarthritic knee. Osteoarthritis Cartilage 2007, 15:673-681.
40. Polisson RP, Schoenberg OI, Fischman A, et al. Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:819-825.
41. 11C-D-deprenyl in patients with rheumatoid arthritis. Scand J Rheumatol 1997, 26:43-48.
42. Goerres GW, Forster A, Uebelhart D, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med 2006, 31:386-390.
43. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-poistron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004, 22:3255-3260.
44. Pandit N, Gonen M, Krug L, Larson SM Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2003, 30:78-84.
45. 18F-FDG PET in rheumatoid arthritis: there still is a long way to go. J Nucl Med 2004, 45:927-929.